Doxazosin
Catalog No. A17779
Doxazosin is an α-1 adrenergic receptor blocker that inhibits the binding of norepinephrine, which is released from sympathetic nerve terminals, to the α-1 receptors on the membrane of vascular smooth muscle cells. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity.
Catalog Num | A17779 |
---|---|
M. Wt | 451.48 |
Formula | C23H25N5O5 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 74191-85-8 |
Synonyms | Doxazosin; Cardura; 74191-85-8; Doxazosinum; Doxazosina; Doxazosine; Alfamedin; Aliud Brand of Doxazosin Mesylate; Almirall Brand of Doxazosin Mesylate; Alpharma Brand of Doxazosin Mesylate; Alter Brand of Doxazosin Mesylate; Apo Doxazosin; Apo-Doxazosin; |
SMILES | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC |
Doxazosin is an α-1 adrenergic receptor blocker that inhibits the binding of norepinephrine, which is released from sympathetic nerve terminals, to the α-1 receptors on the membrane of vascular smooth muscle cells. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity.
In vitro | DMSO | 29 mg/mL (64.23 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 22.15 mL | 110.75 mL | 221.49 mL |
0.5 mM | 4.43 mL | 22.15 mL | 44.3 mL |
1 mM | 2.21 mL | 11.07 mL | 22.15 mL |
5 mM | 0.44 mL | 2.21 mL | 4.43 mL |
*The above data is based on the productmolecular weight 451.48. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.